Abstract
Recently, δ opioid receptor agonists have been proposed to be attractive targets for the development of novel antidepressants. Several studies revealed that single treatment of δ opioid receptor agonists produce antidepressant-like effects in the forced swimming test, which is one of the most popular animal models for screening antidepressants. In addition, subchronic treatment with δ opioid receptor agonists has been shown to completely attenuate the hyperemotional responses found in olfactory bulbectomized rats. This animal model exhibits hyperemotional behavior that may mimic the anxiety, aggression, and irritability found in depressed patients, suggesting that δ opioid receptor agonists could be effective in the treatment of these symptoms in depression. On the other hand, prototype δ opioid receptor agonists produce convulsive effects, which limit their therapeutic potential and clinical development. In this review, we presented the current knowledge regarding the antidepressant-like effects of δ opioid receptor agonists, which include some recently developed drugs lacking convulsive effects.
Keywords: Anxiety, depression, KNT-127, naltrindole, SNC80, TAN-67
Current Neuropharmacology
Title:Antidepressant-like Effects of δ Opioid Receptor Agonists in Animal Models
Volume: 10 Issue: 3
Author(s): Akiyoshi Saitoh and Mitsuhiko Yamada
Affiliation:
Keywords: Anxiety, depression, KNT-127, naltrindole, SNC80, TAN-67
Abstract: Recently, δ opioid receptor agonists have been proposed to be attractive targets for the development of novel antidepressants. Several studies revealed that single treatment of δ opioid receptor agonists produce antidepressant-like effects in the forced swimming test, which is one of the most popular animal models for screening antidepressants. In addition, subchronic treatment with δ opioid receptor agonists has been shown to completely attenuate the hyperemotional responses found in olfactory bulbectomized rats. This animal model exhibits hyperemotional behavior that may mimic the anxiety, aggression, and irritability found in depressed patients, suggesting that δ opioid receptor agonists could be effective in the treatment of these symptoms in depression. On the other hand, prototype δ opioid receptor agonists produce convulsive effects, which limit their therapeutic potential and clinical development. In this review, we presented the current knowledge regarding the antidepressant-like effects of δ opioid receptor agonists, which include some recently developed drugs lacking convulsive effects.
Export Options
About this article
Cite this article as:
Saitoh Akiyoshi and Yamada Mitsuhiko, Antidepressant-like Effects of δ Opioid Receptor Agonists in Animal Models, Current Neuropharmacology 2012; 10 (3) . https://dx.doi.org/10.2174/157015912803217314
DOI https://dx.doi.org/10.2174/157015912803217314 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Suggestion and Pain in Migraine: A Study by Laser Evoked Potentials
CNS & Neurological Disorders - Drug Targets Could Sigma Receptor Ligands be a Treatment for Methamphetamine Addiction?
Current Drug Abuse Reviews Maintenance CBT in Preventing Relapse in Patients on SSRI Continuation
Current Psychopharmacology Putative Immune Regulatory Role of Statins
Current Immunology Reviews (Discontinued) Trends in Enzyme Inhibition and Activation in Drug Design – Part-I
Current Topics in Medicinal Chemistry Progress and Prospects of Stem Cells in Treatment of Drug Resistant Tuberculosis
Current Respiratory Medicine Reviews Role of Wnt Signaling in Tissue Fibrosis, Lessons from Skeletal Muscle and Kidney
Current Molecular Medicine Antioxidants in Wild Mushrooms
Current Medicinal Chemistry Green Tea Extract-Patents and Diversity of Uses
Recent Patents on Food, Nutrition & Agriculture Analgesics in Pregnancy: An Update on Use, Safety and Pharmacokinetic Changes in Drug Disposition
Current Pharmaceutical Design Glycine Transporter Type-1 and its Inhibitors
Current Medicinal Chemistry Possible Pathomechanisms Responsible for Injury to the Central Nervous System in the Settings of Chronic Cerebrospinal Venous Insufficiency
Reviews on Recent Clinical Trials Tyrosine Kinase Inhibitor Resistance and Epigenetic Regulation of SHP1 Phosphatase Expression in Chronic Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Vascular Toxicity of Chemotherapeutic Agents
Current Vascular Pharmacology Structures of the First Extracellular Domain of CRF Receptors
Current Molecular Pharmacology Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'
Current Medicinal Chemistry The Vasopressin V1b Receptor as a Therapeutic Target in Stress-related Disorders
Current Drug Targets - CNS & Neurological Disorders Nephrotoxicity of Bisphenol A (BPA) -An Updated Review
Current Molecular Pharmacology Role of Mitochondrial Protein Quality Control in Oxidative Stress-induced Neurodegenerative Diseases
Current Alzheimer Research Bivalent Ligands for G Protein-Coupled Receptors
Current Pharmaceutical Design